An interventional study of DTx for pain software and Control software in Chronic Low Back Pain, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-08.
Sponsored by Orion Corporation, Orion Pharma · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Low Back Pain with a site in Finland — 3 open to participants now, 4 under way, none of them phase 3. Low Back Pain · Finland.
Among the 16 studies in Low Back Pain with a site in Finland, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 13 with no phase, and was the 11th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →3 of the 16 studies in Low Back Pain with a site in Finland are open now. Recruiting first, the newest first:
Kuopio University Hospital · Sites in Finland
Ages 20–85
Oulu University Hospital · Sites in Finland
University of Oulu · Sites in Finland
Ages 18+
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2020.
This study's enrollment of 34 is below the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 175 across the 15 interventional studies, 63 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Low Back Pain with a site in Finland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, randomised, double-blind, 3-arm parallel group comparison of 2 different virtual reality softwares and standard care.
Prospective, randomised, double-blind, 3-arm parallel group comparison of DTx for pain (treatment A), control (treatment B) and an open standard care arm, over 6-8 weeks. An optional adaptive, multi-objective, multi-purpose, extension is included. Study devices will be delivered to the patient's home with instructions for use; patients will receive remote technical support.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A software
Other: DTx for pain software
Treatment B software
Other: Control software
Pain medication
Other: Standard care
Software with active intervention
Software without active intervention
Pain medication
Self-report of disability, Oswestry
Oswestry Disability Index (subjects with a score of ≤22 will be considered as responders), index 0%-100% (0=no disability, 100=maximum disability possible).
Time frame: From randomisation upto 6-8 weeks
Self-report of disability; Pain Interference
The Patient Reported Outcomes Information System (PROMIS) 6b - Pain Interference Scale, score 6-30 (6=pain not at all interfering patient's life, 30=maximum interfering to patient's life).
Time frame: From randomisation upto 6-8 weeks
Objective report of disability, steps
Average number of steps per day over one week, as assessed by wearable equipment, 0-maximum amount of steps (0=patient not taking steps at all, maximum disability; maximum number of steps=minimum disability).
Time frame: From randomisation upto 6-8 weeks
Fear of movement and re-injury
Tampa Scale of Kinesiophobia (TSK), score 17-68 (17=negligible or no kinesiophobia,68=extreme fear of pain with movement).
Time frame: From randomisation upto 6-8 weeks
Pain Behaviour, pain intensity
Numerical Rating Scale, PROMIS 3a - Pain Intensity Scale, score 3-15 (3=no pain,15=very severe pain).
Time frame: From randomisation upto 6-8 weeks
Pain Behaviour, pain medications
Any changes in pain medication during the study period are reported as outcome.
Time frame: From randomisation upto 6-8 weeks
Quality of life, own experience
EuroQol-5D-5L-scale: European Quality (EQ) of Life (l), 5-dimension-5-level-scale. a). Descriptive System, 5-dimension-5-level-scale, scores are converted to a value where 1 equals 'perfect health' and 0 equals 'dead'. b). Visual Analogue Score, score 0 to 100 where 100 is the best health you can imagine and 0 = the worst health you can imagine.
Time frame: From randomisation upto 6-8 weeks
Quality of life, adverse events
Adverse Event reporting, number of adverse events and their severity
Time frame: From randomisation upto 6-8 weeks
Quality of life, change
Patient Clinical Global Impression of Change (PGIC) results, score 1-7 (1=very much improved, 7=very much worse).
Time frame: From randomisation upto 6-8 weeks
Plan to share: No
Ran from Feb 2020 to primary completion in Oct 2023, 44 months.
Of 56 industry-sponsored interventional studies with no phase under Low Back Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 44 months is above that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma →